# A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

> **NCT04201418** · — · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 67 (actual)

## Conditions studied

- Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
- Polyneuropathy

## Interventions

- **DRUG:** Patisiran

## Key facts

- **NCT ID:** NCT04201418
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-18
- **Primary completion:** 2022-05-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201418, "A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04201418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*